News: OPT Opthea Ltd Receives Commitments From Investors In Australia And United Kingdom To Raise..., page-10

The raise amount looks like a smart move and timely given the dogs were playing the stock price.

Minimizes dilution, keeps us out of CR territory for at least another year but in the meantime we have a likely positive study results event. Also, for the reasons outlined by GS, we have no urgency to do a deal with pharma now and have demonstrated to investment community and potential buyout companies the ease at which we can raise $50M lots to keep funding us through phase 3.

A great set of study numbers next year and we can raise another $50M at maybe half the dilution of this CR.